Market capitalization | $18.80b |
Enterprise Value | $24.53b |
P/E (TTM) P/E ratio | 42.52 |
EV/FCF (TTM) EV/FCF | 28.78 |
EV/Sales (TTM) EV/Sales | 1.96 |
P/S ratio (TTM) P/S ratio | 1.51 |
P/B ratio (TTM) P/B ratio | 2.34 |
Dividend yield | 1.20% |
Last dividend (FY23) | $2.68 |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
18 Analysts have issued a Laboratory forecast:
18 Analysts have issued a Laboratory forecast:
Jun '24 |
+/-
%
|
||
Revenue | 12,488 12,488 |
11%
11%
|
|
Gross Profit | 3,259 3,259 |
9%
9%
|
|
EBITDA | 1,785 1,785 |
21%
21%
|
EBIT (Operating Income) EBIT | 1,135 1,135 |
24%
24%
|
Net Profit | 450 450 |
46%
46%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Laboratory Corp. of America Holdings is a clinical laboratory company. The firm engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the following segments: LabCorp Diagnostics and Covance Drug Development. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing. The Covance Drug Development segment provides drug development solutions to companies in the pharmaceutical and biotechnology industries. The company was founded in 1971 and is headquartered in Burlington, NC.
Head office | United States |
CEO | Adam Schechter |
Employees | 67,000 |
Founded | 1971 |
Website | www.labcorp.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.